{"id":"hydroxychloroquine-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinopathy"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis"}]},"_chembl":{"chemblId":"CHEMBL1535","moleculeType":"Small molecule","molecularWeight":"335.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and reduces antigen presentation and T-cell activation, making it effective in autoimmune diseases. Prednisone is a systemic corticosteroid that broadly suppresses immune cell function and inflammatory cytokine production. Together, this combination targets multiple pathways of immune dysregulation.","oneSentence":"Hydroxychloroquine suppresses immune activation and inflammatory responses, while prednisone provides corticosteroid-mediated immunosuppression and anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:15.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune or inflammatory conditions (specific indication not publicly detailed for this Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT05841758","phase":"PHASE4","title":"Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-07-30","conditions":"Sarcoidosis, Pulmonary","enrollment":140},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT06887517","phase":"","title":"Chinese Rheumatism Biobank(CRB)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-02-10","conditions":"Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT06479304","phase":"NA","title":"The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP","status":"RECRUITING","sponsor":"Yunfeng Cheng","startDate":"2024-04-24","conditions":"Immune Thrombocytopenia With Positive ANA Antibodies","enrollment":129},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT05666336","phase":"PHASE4","title":"Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2022-12-31","conditions":"Systemic Lupus Erythematosus","enrollment":30},{"nctId":"NCT04918524","phase":"","title":"The Clinical Features and Pregnancy Outcomes of CTD Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-09-11","conditions":"Connective Tissue Diseases, Pregnancy Related","enrollment":126},{"nctId":"NCT03855007","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2016-01-01","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT04976465","phase":"PHASE1","title":"Treatment and Clinical Outcomes Among SLE Patients in Pregnancy","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-01-01","conditions":"Systemic Lupus Erythematosus, Pregnancy Related","enrollment":200},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT05644210","phase":"","title":"Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-10-01","conditions":"Antiphospholipid Syndrome","enrollment":80},{"nctId":"NCT05247554","phase":"PHASE3","title":"Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-01","conditions":"Pulmonary Sarcoidosis","enrollment":200},{"nctId":"NCT04380818","phase":"NA","title":"Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19","status":"UNKNOWN","sponsor":"Grupo de Investigación Clínica en Oncología Radioterapia","startDate":"2020-06-05","conditions":"Pneumonia, Viral","enrollment":106},{"nctId":"NCT04569890","phase":"NA","title":"Treatment of Pregnancy RA","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-12-01","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT01946880","phase":"PHASE2","title":"Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-11-20","conditions":"Systemic Lupus Erythematosus, SLE","enrollment":102},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":"Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss","enrollment":420},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT02558517","phase":"PHASE3","title":"Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus","status":"UNKNOWN","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2014-01","conditions":"Systemic Lupus Erythematosus","enrollment":136},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02200146","phase":"PHASE3","title":"Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2009-03","conditions":"Pulmonary Sarcoidosis","enrollment":94},{"nctId":"NCT00031824","phase":"PHASE3","title":"Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-04","conditions":"Graft Versus Host Disease","enrollment":82}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":571,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxychloroquine + Prednisone","genericName":"Hydroxychloroquine + Prednisone","companyName":"University of Milano Bicocca","companyId":"university-of-milano-bicocca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxychloroquine suppresses immune activation and inflammatory responses, while prednisone provides corticosteroid-mediated immunosuppression and anti-inflammatory effects. Used for Autoimmune or inflammatory conditions (specific indication not publicly detailed for this Phase 3 trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}